PAR2026-01-012026-03-31PAR2026-03-31PAR2025-03-31PAR2025-04-012026-03-31PAR2026-01-012026-03-31in-capmkt:OtherExpenses1MemberPAR2025-04-012026-03-31in-capmkt:OtherExpenses1MemberPAR2026-03-31OtherNoncurrentAssetsDomain1PAR2026-03-31OtherCurrentAssetsDomain1PAR2026-03-31OtherCurrentLiabilitiesDomain1PAR2026-01-012026-03-31RelatedPartyTransactionDomain1PAR2025-12-31RelatedPartyTransactionDomain1PAR2026-03-31RelatedPartyTransactionDomain1PAR2026-01-012026-03-31RelatedPartyTransactionDomain2PAR2025-12-31RelatedPartyTransactionDomain2PAR2026-03-31RelatedPartyTransactionDomain2PAR2026-01-012026-03-31RelatedPartyTransactionDomain3PAR2025-12-31RelatedPartyTransactionDomain3PAR2026-03-31RelatedPartyTransactionDomain3PAR2026-01-012026-03-31RelatedPartyTransactionDomain4PAR2025-12-31RelatedPartyTransactionDomain4PAR2026-03-31RelatedPartyTransactionDomain4PAR2026-01-012026-03-31RelatedPartyTransactionDomain5PAR2025-12-31RelatedPartyTransactionDomain5PAR2026-03-31RelatedPartyTransactionDomain5PAR2026-01-012026-03-31RelatedPartyTransactionDomain6PAR2025-12-31RelatedPartyTransactionDomain6PAR2026-03-31RelatedPartyTransactionDomain6PAR2026-01-012026-03-31RelatedPartyTransactionDomain7PAR2025-12-31RelatedPartyTransactionDomain7PAR2026-03-31RelatedPartyTransactionDomain7PAR2026-01-012026-03-31RelatedPartyTransactionDomain8PAR2025-12-31RelatedPartyTransactionDomain8PAR2026-03-31RelatedPartyTransactionDomain8PAR2026-01-012026-03-31RelatedPartyTransactionDomain9PAR2025-12-31RelatedPartyTransactionDomain9PAR2026-03-31RelatedPartyTransactionDomain9PAR2026-01-012026-03-31RelatedPartyTransactionDomain10PAR2025-12-31RelatedPartyTransactionDomain10PAR2026-03-31RelatedPartyTransactionDomain10PAR2026-01-012026-03-31RelatedPartyTransactionDomain11PAR2025-12-31RelatedPartyTransactionDomain11PAR2026-03-31RelatedPartyTransactionDomain11PAR2026-01-012026-03-31RelatedPartyTransactionDomain12PAR2025-12-31RelatedPartyTransactionDomain12PAR2026-03-31RelatedPartyTransactionDomain12PAR2026-01-012026-03-31RelatedPartyTransactionDomain13PAR2025-12-31RelatedPartyTransactionDomain13PAR2026-03-31RelatedPartyTransactionDomain13PAR2026-01-012026-03-31RelatedPartyTransactionDomain14PAR2025-12-31RelatedPartyTransactionDomain14PAR2026-03-31RelatedPartyTransactionDomain14PAR2026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares000000PARNOTLISTEDINE04LG01015PAR DRUGS AND CHEMICALS LIMITEDMain BoardEquity2025-04-012026-03-312026-05-142026-05-06INRLakhsQuarterlyFourth quarterSingle segmentThe Company is primarily engaged in manufacturing of API, which constitute single business segment in terms of Ind AS - 108 on “Operating Segments”. Accordingly, there are no separate reportable segments as per Ind AS - 108.2026-05-1415:30:002026-05-1418:16:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2026-02-10https://pardrugs.com/pdf/policies/Revised_Policy_on_Related_Party_Tranactions.pdffalsefalseAs there is no any outstanding default on loans and debt securities as on 31.03.2026 hence not applicale to the company.2026-01-012026-03-31AuditedStandalone1961080003585000199693000884590000626000193540004140009275000732500001913780008315000083150003139000-3360000-221000085360000000853600008536000123046000100.690.69000.690.69Notes <BR> <BR> 1. The standalone financial results of the Company have been prepared in accordance with the Ind AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, other accounting principles generally accepted in India and in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, including relevant circulars issued by the SEBI from time to time. <BR> <BR> 2. The above quarterly and year to date financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14th May, 2026. <BR> <BR> 3. The Auditor of the company have carried out audit of the financial results for the quarter and year ended 31st March, 2026 in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015 and have expressed their unmodified opinion. <BR> <BR> 4. Figures for the quarter ended 31st March, 2026 are balancing figures between audited figures in respect of full financial year and the published year to date figures of the quarter ended 31st December, 2025. The figures up to the quarter ended 31st December, 2025 were subject to limited review. <BR> <BR> 5. The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earnings per share (not annualized) in accordance with the Ind AS. <BR> <BR> 6. Previous year / period figures have been regrouped / rearranged wherever necessary to make them comparable with current period figures. <BR> <BR> 7. The Company is primarily engaged in manufacturing of API, which constitute single business segment in terms of Ind AS - 108 on “Operating Segments”. Accordingly, there are no separate reportable segments as per Ind AS - 108. <BR> <BR> <BR> 8. The Company does not have any subsidiary, associates or joint venture as on 31st March, 2026; therefore, it has prepared only standalone results as consolidation requirement is not applicable to the Company. <BR> <BR> 9. The above financial results of the Company are available on the Company’s website – www.pardrugs.com and on the website of the National Stock Exchange of India Limited (www.nseindia.com), where the Company’s shares are listed. <BR> <BR> 10. The Status of investors complaints are as follows: <BR> I. Pending at the beginning of the quarter - 0 <BR> II. Received during the quarter - 4 <BR> III. Disposed-off during the quarter - 4 <BR> IV. Remaining unresolved at the end of the quarter - 0 <BR> 2025-04-012026-03-31AuditedStandalone10365560004000700010765630004267050000690900061201000127300037033000370426000903547000173016000017301600045290000-3360000419300000131086000000013108600001310860001230460001099680000010.6510.650010.6510.65Other expenses73250000Other expenses370426000364386000717000000271364000027136400059440006488640005372800001202770004184290000111200053981800047476000223700064325900012921230001230460009968000001119846000111984600000240100032440000348410000800600073933000819390008193900095900004590700001374360001722770001292123000Other non-current assets5944000Other Current Assets2237000Other Current Liabilities959000007331000468640000-1147000-503000000-269750000-1385000037033000070000-265000000000000-194270000041596000214612000000502900000164322000000000002340001961700002066400000000000000000001838300000-2166400000000000000000001426580000142658000275772000418430000Par Drugs And Chemicals Limited******Falgunbhai V Savani******Managing DirectorRemunerationNil2575000299000304000By considering the suggestion and approval of Nomination & Remuneration Committee and approval of Audit Committee held on 16/08/2023, the Board at its meeting held on 17/08/2023 considered and approved re-appointment and fixed remuneration payable, which is subsequently approved by the shareholders for a period of 5 years w.e.f. 26th Day of November, 2023 to 25th Day of November, 2028 in the 24th Annual General Meeting held on Saturday, 16th Day of September, 2023 at 11:00 A.M. at Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, India. Par Drugs And Chemicals Limited******Falgunbhai V Savani******Managing DirectorAny other transactionSitting FeesNil4000000 By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.Par Drugs And Chemicals Limited******Jigneshbhai V Savani******Director & CEORemunerationNil2575000314000319000By considering the suggestion and approval of Nomination & Remuneration Committee and approval of Audit Committee held on 16/08/2023, the Board at its meeting held on 17/08/2023 considered and approved re-appointment and fixed remuneration payable, which is subsequently approved by the shareholders for a period of 5 years w.e.f. 26th Day of November, 2023 to 25th Day of November, 2028 in the 24th Annual General Meeting held on Saturday, 16th Day of September, 2023 at 11:00 A.M. at Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, India. Par Drugs And Chemicals Limited******Jigneshbhai V Savani******Director & CEOAny other transactionSitting FeesNil2500000 By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.Par Drugs And Chemicals Limited******Ghanshyambhai B Savani******Prodcution Head (Promoter Group)RemunerationNil6850004290000Par Drugs And Chemicals Limited******Savani Prathambhai Ghanshyambhai******Relative of Promoter Group (Son of Ghanshyambhai B. Savani)RemunerationNil1920002700027000Par Drugs And Chemicals Limited******Sanket Bhupendrabhai Trivedi******Company SecretaryRemunerationNil3900005700057000Par Drugs And Chemicals Limited******Chintan Pratapbhai Chauhan******Chief Financial OfficerRemunerationNil3620005300053000Par Drugs And Chemicals Limited******Kajal Chitanbhai Vaghani******Independent DirectorAny other transactionSitting FeesNil45000010000 By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.Par Drugs And Chemicals Limited******Krishna Mitulbhai Shah******Independent DirectorAny other transactionSitting FeesNil65000023000 By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.Par Drugs And Chemicals Limited******Pravin Manjibhai Bhayani******Independent DirectorAny other transactionSitting FeesNil6500000 By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.Par Drugs And Chemicals Limited******Pravin Manjibhai Bhayani******Independent DirectorRemunerationNil1200000180000203000By considering the suggestion and approval of Nomination & Remuneration Committee and approval of Audit Committee held on 29/08/2025, the Board at its meeting held on 29/08/2025 considered and approved remuneration payable, which is subsequently approved by the shareholders for the period of one year w.e.f. 1st October, 2025 to 30th September, 2026, payable on a monthly, quarterly, half yearly or yearly basis, as decided by the Board of Directors of the Company in the 26th Annual General Meeting held on Saturday, 27th Day of September, 2025 at 11:00 A.M. at Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, IndiaPar Drugs And Chemicals Limited******Bintal Bhaveshkumar Shah******Independent DirectorAny other transactionSitting FeesNil40000020000 By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.Par Drugs And Chemicals Limited******Phal Jig Fine Chemicals Private Limited******Enterprise in which significant influence is exercised by KMPAny other transactionAdvance money received950000000Nil051000005100000By considering the suggestion and approval of Audit Committee and Board meeting held on 11/01/2025 considered and approved the transaction , which is subsequently approved by the shareholders in the Extra-Ordinary General Meeting (“EGM”) (Meeting No. 02/EGM/2024-25) of the Members of PAR DRUGS AND CHEMICALS LIMITED (“Company”) held on Wednesday, 12th Day of February, 2025 at 3:00 P.M. (IST) through Video Conferencing (“VC”) / Other Audio Visual Means (“OAVM”)8259000AuditedtrueSARUPRIA SOMANI & ASSOCIATEStrue2028-08-31